We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+52.39%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$498M
AUM Growth
+$154M
Cap. Flow
+$62.8M
Cap. Flow %
12.62%
Top 10 Hldgs %
81.5%
Holding
55
New
24
Increased
13
Reduced
1
Closed
6

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.2M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$11.6M
3
MRK icon
Merck
MRK
+$6.16M
4
IRON icon
Disc Medicine
IRON
+$5.64M
5
CYTK icon
Cytokinetics
CYTK
+$4.44M

Top Sells

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$3.54M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$2.79M
3
WAT icon
Waters Corp
WAT
+$937K
4
TYRA icon
Tyra Biosciences
TYRA
+$142K

Sector Composition

Rank Sector Weight
1 Healthcare 81.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
26
DELISTED
Verona Pharma
VRNA
$2.1M 0.42%
130,790
– –
ALPN
27
DELISTED
Alpine Immune Sciences Inc
ALPN
$2.05M 0.41%
+51,714
New +$1.53M
CRL icon
28
Charles River Laboratories
CRL
$11.3B
$1.87M 0.38%
6,905
– –
JANX icon
29
Janux Therapeutics
JANX
$973M
$1.81M 0.36%
+47,949
New +$1.04M
SLNO
30
DELISTED
Soleno Therapeutics
SLNO
$1.75M 0.35%
+40,924
New +$1.85M
XENE icon
31
Xenon Pharmaceuticals
XENE
$6.19B
$1.72M 0.35%
+40,000
New +$1.84M
ARVN icon
32
Arvinas
ARVN
$581M
$1.65M 0.33%
+40,000
New +$1.75M
PLRX icon
33
Pliant Therapeutics
PLRX
$65M
$1.49M 0.3%
100,000
– –
MREO
34
Mereo BioPharma
MREO
$51.4M
$1.39M 0.28%
+421,359
New +$1.43M
NAMS icon
35
NewAmsterdam Pharma
NAMS
$3.22B
$1.28M 0.26%
+54,285
New +$1.1M
RAPT
36
DELISTED
RAPT Therapeutics
RAPT
$1.23M 0.25%
17,164
+14,709
+599% +$2.05M
SLN
37
Silence Therapeutics
SLN
$528M
$1.13M 0.23%
+52,476
New +$1.14M
EYPT icon
38
EyePoint Inc
EYPT
$978M
$1.06M 0.21%
51,500
+1,500
+3% +$37.1K
ANNX icon
39
Annexon
ANNX
$873M
$1.06M 0.21%
+147,485
New +$766K
VERA icon
40
Vera Therapeutics
VERA
$2.15B
$1.05M 0.21%
+24,298
New +$866K
MGNX icon
41
MacroGenics
MGNX
$248M
$942K 0.19%
+64,007
New +$967K
KURA icon
42
Kura Oncology
KURA
$841M
$842K 0.17%
+39,478
New +$767K
IMVT icon
43
Immunovant
IMVT
$8.08B
$691K 0.14%
21,397
– –
BMEA icon
44
Biomea Fusion
BMEA
$88.9M
$530K 0.11%
35,452
+10,000
+39% +$165K
LRMR icon
45
Larimar Therapeutics
LRMR
$427M
$442K 0.09%
+58,190
New +$453K
MDGL icon
46
Madrigal Pharmaceuticals
MDGL
$11.7B
$416K 0.08%
+1,557
New +$367K
EFTR
47
CALL
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$360K 0.07%
+25,000
New +$299K
PSTX
48
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$274K 0.06%
+86,002
New +$287K
GRTS
49
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$245K 0.05%
95,170
– –
BMRN icon
50
BioMarin Pharmaceuticals
BMRN
$11.7B
– –
-28,885
Closed -$2.79M
1
2
3

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $498M AUM 20.41% 1-Year Est. Return

Artia Global Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Artia Global Partners held 55 positions worth $498M, up 45% from $344M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Artia Global Partners deployed $62.8M of net new capital in Q1 2024, opening 24 new positions and adding to 13 existing holdings. Its largest new stake was Vertex Pharmaceuticals: 28,900 shares worth $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 74% a quarter earlier.

On the sell side, the largest reduction was Novo Nordisk, an estimated $3.54M trimmed.

  • Artia Global Partners's largest Q1 2024 buy was Vertex Pharmaceuticals: 28,900 shares worth $12.1M.
  • Artia Global Partners added most to Intra-Cellular Therapies Inc. in Q1 2024, an estimated $11.6M increase.
  • Artia Global Partners's biggest Q1 2024 reduction was Novo Nordisk, cutting an estimated $3.54M.
  • Artia Global Partners fully exited BioMarin Pharmaceuticals in Q1 2024, selling an estimated $2.79M.
  • Artia Global Partners's ten largest holdings make up 81% of its $498M portfolio in Q1 2024.
  • Artia Global Partners opened 24 new positions and closed 6 in Q1 2024.
  • Artia Global Partners's portfolio value rose 45% quarter-over-quarter to $498M.

Based on Artia Global Partners's 13F filing for Q1 2024, filed 15 May 2024.